Therapeutic advances in neurological disorders · 2026
Insights into adherence to cladribine tablets in the real world in multiple countries: results from patient support programs.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oh Jiwon, Ayer Mavis, Alroughani Raed, Farouk Samar, Khoury Mounir, de Souza Sabrina, Bossolasco Michela, Morgan Kate, Negrotto Laura, Quinn Tracey, Boshra Amir, Youssef Joseph, Al-Naqshbandi Murad, MacDonald Kelly, Sabidó Meritxell, Muir Jeffrey M, Silva Berenice
Аннотация
BACKGROUND: Patient support programs (PSP) help initiate and maintain disease-modifying treatment (DMT) for people with multiple sclerosis (PwMS). adveva® (worldwide), Alcura Healthcare (Netherlands), and MS LifeLines® (US) are nurse-pharmacy-led PSPs that collect clinical information, with consent, on PwMS receiving cladribine tablets (3.5 mg/kg over 2 years followed by a 2-year treatment-free period per product label).
OBJECTIVE: To evaluate initiation and completion of short courses of cladribine tablets treatment in Years 1 and 2 for PwMS and the frequency of subsequent treatment.
DESIGN: Retrospective, multinational, observational study using real-world data from PSPs.
METHODS: Clinical data from PSPs in Australia, Canada, Gulf, Latin America, Near East, Netherlands, UK, and US (December 2017-December 2023) included prior DMT use, cladribine tablets initiation and completion (Years 1 and 2), and subsequent treatment after Year 2 for those with ⩾48 months' follow-up.
RESULTS: Across all PSPs, 22,082 PwMS initiated cladribine tablets (Australia, n = 799; Canada, n = 3665; Gulf, n = 258; Latin America, n = 1854; Near East, n = 86; Netherlands, n = 681; UK, n = 2320; US, n = 12,418), of whom 70.9%-81.3% were female (mean age 34.2-49.1 years). Most were DMT-experienced (Australia, no contribution to analysis; Canada, 100%; Gulf, 52.7%; Latin America, 57.7%; Near East, 86.0%; Netherlands, 81.4%; UK, 30.0%; US, 79.5%) with oral DMTs most commonly used (36.5%-69.3%). In PwMS with ⩾18 months' follow-up, ⩾82.8% initiated Year 2 treatment at a mean of 12.4 (±3.8) to 13.9 (±3.5) months after initiating Year 1 treatment. Of those commencing Year 2 treatment, ⩾93.6% completed it. Additional treatment with cladribine tablets beyond 48 months was administered in a small proportion of PwMS: Canada, 5.6%; Latin America, 4.3%; Netherlands, 3.8%; and UK, 1.8%.
CONCLUSION: Cladribine tablets adherence was high, with most PwMS completing short-course cladribine tablets treatment in Years 1 and 2. Of those with ⩾48 months' follow-up, only a small proportion received additional cladribine tablets treatment.
OBJECTIVE: To evaluate initiation and completion of short courses of cladribine tablets treatment in Years 1 and 2 for PwMS and the frequency of subsequent treatment.
DESIGN: Retrospective, multinational, observational study using real-world data from PSPs.
METHODS: Clinical data from PSPs in Australia, Canada, Gulf, Latin America, Near East, Netherlands, UK, and US (December 2017-December 2023) included prior DMT use, cladribine tablets initiation and completion (Years 1 and 2), and subsequent treatment after Year 2 for those with ⩾48 months' follow-up.
RESULTS: Across all PSPs, 22,082 PwMS initiated cladribine tablets (Australia, n = 799; Canada, n = 3665; Gulf, n = 258; Latin America, n = 1854; Near East, n = 86; Netherlands, n = 681; UK, n = 2320; US, n = 12,418), of whom 70.9%-81.3% were female (mean age 34.2-49.1 years). Most were DMT-experienced (Australia, no contribution to analysis; Canada, 100%; Gulf, 52.7%; Latin America, 57.7%; Near East, 86.0%; Netherlands, 81.4%; UK, 30.0%; US, 79.5%) with oral DMTs most commonly used (36.5%-69.3%). In PwMS with ⩾18 months' follow-up, ⩾82.8% initiated Year 2 treatment at a mean of 12.4 (±3.8) to 13.9 (±3.5) months after initiating Year 1 treatment. Of those commencing Year 2 treatment, ⩾93.6% completed it. Additional treatment with cladribine tablets beyond 48 months was administered in a small proportion of PwMS: Canada, 5.6%; Latin America, 4.3%; Netherlands, 3.8%; and UK, 1.8%.
CONCLUSION: Cladribine tablets adherence was high, with most PwMS completing short-course cladribine tablets treatment in Years 1 and 2. Of those with ⩾48 months' follow-up, only a small proportion received additional cladribine tablets treatment.